Grant RDF
pages:- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- more...
- A Phase 3, International Multi-Center Randomized Double Blind Placebo Controlled Parallelgroup Efficacy and Safety......
- A Phase 3, Multctr, Randomized, Plcb-Contrld, Dbl-Bld, Three-Armstudy to Evaluate the Safety and Efficacy of Tifacogin . . .
- A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of Pegylated Rfviii (Bax855) in Previously Treated .
- A Phase 3, Multicenter Randomized Active-Controlled Study to Investigate the Dafety and Efficacy of Psi-7977.....
- A Phase 3, Multicenter, Double-Blind,...to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients..
- A Phase 3, Multicenter, Open-label Study to Investigate the Efficacy and Safety of GS-7977 with Peg interferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1, 4, 5, or 6 HCV Infection
- A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed-Dose . . .
- A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis
- A Phase 3, Multicenter, Open-Label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone...
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 or 3 HCV Infection who are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment Experienced Subjects with Chronic Genotype 2 or 3 HCV Infection
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide (Pom)...
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/Gs-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection’
- A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy & Saftety of Sofosbuvir/Lrdipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Saftety of Sofosbuvir/Gs-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection
- A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn's Disease
- A Phase 3, Open-Label, Follow-On Study of Multiple Courses of Aztreonam Lysinate for Inhalation (Ai) in Cystic .........
- A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of An Induction
- A Phase 3, Randm, Placebo-Cont, Bld-Multi, for the Induction& Mtn of Clinical Response & Remission With Mln0002-C13006
- A Phase 3, Randm, Placebo-Cont, Bld-Multi, for the Induction& Mtn of Clinical Response & Remission With Mln0002-C13007
- A Phase 3, Randomized Double Blind, Multicenter Study Comparing Oral Mln9708 Plus Lenalidomide and Dexamethasone..
- A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or